Proto Script Pharmaceutical Corp.
Other OTCTotal Valuation
Proto Script Pharmaceutical Corp. carries a market capitalization of 9,828.00, placing it among publicly traded companies globally.
| Market Cap | 9,828.00 |
| Enterprise Value | N/A |
Share Statistics
Proto Script Pharmaceutical Corp. currently has 49.14M shares outstanding.
| Shares Outstanding | 49.14M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 5.21, and the price-to-book ratio stands at -0.36.
| PE Ratio | N/A |
| PS Ratio | 5.21 |
| PB Ratio | -0.36 |
| P/TBV Ratio | -2.19 |
| P/FCF Ratio | -11.72 |
| P/OCF Ratio | -10.41 |
Financial Position
Proto Script Pharmaceutical Corp. maintains a current ratio of 0.11, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.11 |
| Quick Ratio | 0.10 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -1.49 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -7,149.53 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Proto Script Pharmaceutical Corp.'s stock has declined approximately -33.33334% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | -33.33334% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Proto Script Pharmaceutical Corp. generated 604,978.00 in revenue and converted that into -8.39M in net income, yielding earnings per share of -0.10. EBITDA reached -962,569.00, while operating income came in at -970,952.00.
| Revenue | 604,978.00 |
| Gross Profit | 351,809.00 |
| Operating Income | -970,952.00 |
| Pretax Income | -8.39M |
| Net Income | -8.39M |
| EBITDA | -962,569.00 |
| EBIT | -970,952.00 |
| Earnings Per Share (EPS) | -0.10 |
Balance Sheet
Total book value stands at -8.69M, with working capital of -1.49M providing operational flexibility.
| Cash & Cash Equivalents | N/A |
| Total Debt | N/A |
| Net Debt | 372,745.00 |
| Equity (Book Value) | -8.69M |
| Book Value Per Share | -0.10 |
| Working Capital | -1.49M |
Cash Flow
Proto Script Pharmaceutical Corp. produced -303,097.00 in operating cash flow over the past twelve months. After subtracting -33,847.00 in capital expenditures, free cash flow totaled -336,944.00 - equivalent to 0.00 per share.
| Operating Cash Flow | -303,097.00 |
| Capital Expenditures | -33,847.00 |
| Free Cash Flow | -336,944.00 |
| FCF Per Share | 0.00 |
Margins
Proto Script Pharmaceutical Corp. operates with a gross margin of 58.15, reflecting its pricing power and cost economics. The operating margin of -160.49 and net profit margin of -1,386.22 provide insight into operational efficiency.
| Gross Margin | 58.15 |
| Operating Margin | -160.49 |
| Pretax Margin | -1,386.22 |
| Profit Margin | -1,386.22 |
| EBITDA Margin | -159.11 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -10.50 |
| FCF Yield | -8.54 |
Stock Splits
Proto Script Pharmaceutical Corp.'s most recent stock split took place on October 13, 2016 with a 1:10 split ratio.
| Last Split Date | 10/13/2016 |
| Split Ratio | 1:10 |
Scores
Proto Script Pharmaceutical Corp. posts an Altman Z-Score of -69.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -69.73 |